Trials / Completed
CompletedNCT00605813
Special Investigation Of Long Term Use Of Sertraline.
Special Investigation Of Long Term Use Of J ZOLOFT.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 542 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Special investigation of long term use of sertraline, 52 Week Observation, Long-Term Safety. The objective of this "Special investigation" is to collect information about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug regarding long time use.
Detailed description
All the patients for whom an investigator prescribes the first sertraline hydrochloride should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sertraline hydrochloride | J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan. Dosage, Frequency: According to Japanese LPD, "The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms". Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2008-01-31
- Last updated
- 2021-01-28
- Results posted
- 2012-09-10
Source: ClinicalTrials.gov record NCT00605813. Inclusion in this directory is not an endorsement.